Today's Daily Dose brings you news about temporary suspension of bluebird bio's gene therapy trials in sickle cell disease, Sesen Bio's regulatory catalyst for this year, partial hold on Cortexyme's open-label extension phase of its ongoing phase II/III study of Atuzaginstat for Alzheimer's disease, and expanded FDA approval of Novartis' Entresto.